Fig. 7From: Prognostic risk assessment model and drug sensitivity analysis of colon adenocarcinoma (COAD) based on immune-related lncRNA pairsCCK-8 assay for the drug. A 24-h inhibitory capacity of CCT007093 drug. B 24-h inhibitory capacity of Embelin drug. C 24-h inhibitory capacity of the drug PAC-1. D 48-h inhibitory capacity of the CCT007093 drug. E 48-h inhibitory capacity of Embelin drug. F 48-h inhibitory capacity of PAC-1 drug. Where 0Â mol/L is the controlBack to article page